AIM ImmunoTech Inc. 8-K

What Happened AIM ImmunoTech Inc. (AIM) announced on April 10, 2026 that it entered into Amendment No. 1 to its April 1, 2025 Equity Distribution Agreement with Maxim Group LLC. The amendment removes the prior limitation on the amount of common stock that may be sold under the Sales Agreement (the original agreement had been limited to up to $3,000,000). The shares will be sold pursuant to the company’s shelf registration statement on Form S-3 (File No. 333-286319). AIM also filed a prospectus supplement the same day to increase the number of shares that may be offered.

Key Details

• Amendment No. 1 executed April 10, 2026, with Maxim Group LLC as AIM’s exclusive sales agent.
• The prior cap of up to $3,000,000 in sales under the Sales Agreement was removed.
• Sales will occur as an at-the-market (ATM) offering under the company’s Form S-3 shelf registration (File No. 333-286319).
• AIM filed a prospectus supplement concurrently to increase the number of shares that may be offered and sold.

Why It Matters This amendment gives AIM greater flexibility to raise capital over time by selling shares into the market through an ATM program handled by Maxim. For investors, additional share issuances can increase the company’s available funding but may also increase the number of outstanding shares, which can affect per-share metrics like earnings per share. Retail investors should monitor future prospectus supplements and sales notices for timing and amounts of any share sales.